DETECTION OF RESIDUAL TUMOR-CELLS IN PATIENTS WITH MALIGNANT-MELANOMA RESPONDING TO IMMUNOTHERAPY
DETECTION OF RESIDUAL TUMOR-CELLS IN PATIENTS WITH MALIGNANT-MELANOMA RESPONDING TO IMMUNOTHERAPY
复制标题
DOI：
10.1097/00002371-199401000-00005
复制
发表时间：
1994-01-01
影响因子：
3.9
通讯作者：
HUNSTEIN, W
中科院分区：
文献类型：
--
作者：
BROSSART, P;KEILHOLZ, U;HUNSTEIN, W
最近，开发了一种结合逆转录和聚合酶链反应（PCR）的高灵敏度检测方法来评估外周血中的黑色素瘤细胞。酪氨酸酶 mRNA（黑色素细胞和黑色素瘤细胞中的一种组织特异性酶）的检测表明外周血中存在黑色素瘤细胞。我们检查了 28 名转移性恶性黑色素瘤患者的血液样本和骨髓抽吸物，以确定在干扰素 (IFN)-α 和白细胞介素 (IL)-2 治疗前后是否存在黑色素瘤细胞。十名患者对免疫疗法表现出抗肿瘤反应，其中三名患者完全缓解（CR），七名患者部分缓解（PR）。 4 名患者（3 名 PR，1 名疾病稳定）随后接受了残留肿瘤病灶的切除，术后没有疾病的临床证据。在免疫治疗前后所有恶性黑色素瘤患者的血液和骨髓样本中均检测到酪氨酸酶 mRNA，包括那些没有疾病临床证据的患者（中位无病生存期 21 个月，范围 19-28 个月）。在所有无黑色素瘤患者中也检测到了酪氨酸酶转录本。相比之下，在 30 名健康人或 6 名患有其他恶性肿瘤的患者中均未检测到酪氨酸酶 mRNA。残留黑色素瘤细胞的存在可能是延迟复发发生的重要指标。
Recently, a highly sensitive assay combining reverse transcription and polymerase chain reaction (PCR) to assess for melanoma cells in peripheral blood has been developed. Detection of tyrosinase mRNA, a tissue-specific enzyme in melanocytes and melanoma cells, indicates the presence of melanoma cells in peripheral blood. We examined blood samples and bone marrow aspirates from 28 patients with metastatic malignant melanoma for presence of melanoma cells prior to and after therapy with interferon (IFN)-alpha and interleukin (IL)-2. Ten patients showed antitumor response to immunotherapy, including three complete (CR) and seven partial remissions (PR). Four patients (three PR, one stable disease) underwent subsequent resection of residual tumor lesions and had no clinical evidence of disease after surgery. Tyrosinase mRNA was detected in blood and bone marrow samples from all patients with malignant melanoma prior to and after immunotherapy, including those with no clinical evidence of disease (median disease-free survival 21 months, range 19-28 months). Tyrosinase transcripts were also detected in all patients with amelanotic melanoma. In contrast, no tyrosinase mRNA was detectable in any of 30 healthy persons or in six patients with other malignancies. The presence of residual melanoma cells may be an important indicator of occurrence of delayed relapse.